Report cover image

Global Parenteral Drugs Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 219 Pages
SKU # APRC20556973

Description

Summary

According to APO Research, the global Parenteral Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Parenteral Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Parenteral Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Parenteral Drugs market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Parenteral Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Parenteral Drugs market include Albert David, Aspen Holdings, AXA Parenterals Ltd, BAG Healthcare, Baxter Healthcare Corporation, Beximco Pharma, BML Parenteral Drugs, Cook Pharmica and Ostuka Pharmaceutical, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Parenteral Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Parenteral Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Parenteral Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Parenteral Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Parenteral Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Parenteral Drugs sales, projected growth trends, production technology, application and end-user industry.

Parenteral Drugs Segment by Company

Albert David
Aspen Holdings
AXA Parenterals Ltd
BAG Healthcare
Baxter Healthcare Corporation
Beximco Pharma
BML Parenteral Drugs
Cook Pharmica
Ostuka Pharmaceutical
Ozon Pharmaceuticals Ltd
Patheon
PSI Ltd
Southwest Pharmaceutical
B. Braun
Cisen
Fresenius
Pfizer (Hospira)
Kelun Pharma
Acebright
SSY Group
Teva Pharmaceutical Industries
Abbott
Parenteral Drugs Segment by Type

LVP Drug
SVP Drug
Parenteral Drugs Segment by Application

Hospitals
Medical Centers
Others
Parenteral Drugs Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global Parenteral Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Parenteral Drugs market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Parenteral Drugs significant trends, drivers, influence factors in global and regions.
6. To analyze Parenteral Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Parenteral Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Parenteral Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Parenteral Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Parenteral Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Parenteral Drugs industry.
Chapter 3: Detailed analysis of Parenteral Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Parenteral Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Parenteral Drugs in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

219 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Parenteral Drugs Sales Value (2020-2031)
1.2.2 Global Parenteral Drugs Sales Volume (2020-2031)
1.2.3 Global Parenteral Drugs Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Parenteral Drugs Market Dynamics
2.1 Parenteral Drugs Industry Trends
2.2 Parenteral Drugs Industry Drivers
2.3 Parenteral Drugs Industry Opportunities and Challenges
2.4 Parenteral Drugs Industry Restraints
3 Parenteral Drugs Market by Company
3.1 Global Parenteral Drugs Company Revenue Ranking in 2024
3.2 Global Parenteral Drugs Revenue by Company (2020-2025)
3.3 Global Parenteral Drugs Sales Volume by Company (2020-2025)
3.4 Global Parenteral Drugs Average Price by Company (2020-2025)
3.5 Global Parenteral Drugs Company Ranking (2023-2025)
3.6 Global Parenteral Drugs Company Manufacturing Base and Headquarters
3.7 Global Parenteral Drugs Company Product Type and Application
3.8 Global Parenteral Drugs Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Parenteral Drugs Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Parenteral Drugs Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Parenteral Drugs Market by Type
4.1 Parenteral Drugs Type Introduction
4.1.1 LVP Drug
4.1.2 SVP Drug
4.2 Global Parenteral Drugs Sales Volume by Type
4.2.1 Global Parenteral Drugs Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Parenteral Drugs Sales Volume by Type (2020-2031)
4.2.3 Global Parenteral Drugs Sales Volume Share by Type (2020-2031)
4.3 Global Parenteral Drugs Sales Value by Type
4.3.1 Global Parenteral Drugs Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Parenteral Drugs Sales Value by Type (2020-2031)
4.3.3 Global Parenteral Drugs Sales Value Share by Type (2020-2031)
5 Parenteral Drugs Market by Application
5.1 Parenteral Drugs Application Introduction
5.1.1 Hospitals
5.1.2 Medical Centers
5.1.3 Others
5.2 Global Parenteral Drugs Sales Volume by Application
5.2.1 Global Parenteral Drugs Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Parenteral Drugs Sales Volume by Application (2020-2031)
5.2.3 Global Parenteral Drugs Sales Volume Share by Application (2020-2031)
5.3 Global Parenteral Drugs Sales Value by Application
5.3.1 Global Parenteral Drugs Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Parenteral Drugs Sales Value by Application (2020-2031)
5.3.3 Global Parenteral Drugs Sales Value Share by Application (2020-2031)
6 Parenteral Drugs Regional Sales and Value Analysis
6.1 Global Parenteral Drugs Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Parenteral Drugs Sales by Region (2020-2031)
6.2.1 Global Parenteral Drugs Sales by Region: 2020-2025
6.2.2 Global Parenteral Drugs Sales by Region (2026-2031)
6.3 Global Parenteral Drugs Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Parenteral Drugs Sales Value by Region (2020-2031)
6.4.1 Global Parenteral Drugs Sales Value by Region: 2020-2025
6.4.2 Global Parenteral Drugs Sales Value by Region (2026-2031)
6.5 Global Parenteral Drugs Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Parenteral Drugs Sales Value (2020-2031)
6.6.2 North America Parenteral Drugs Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Parenteral Drugs Sales Value (2020-2031)
6.7.2 Europe Parenteral Drugs Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Parenteral Drugs Sales Value (2020-2031)
6.8.2 Asia-Pacific Parenteral Drugs Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Parenteral Drugs Sales Value (2020-2031)
6.9.2 South America Parenteral Drugs Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Parenteral Drugs Sales Value (2020-2031)
6.10.2 Middle East & Africa Parenteral Drugs Sales Value Share by Country, 2024 VS 2031
7 Parenteral Drugs Country-level Sales and Value Analysis
7.1 Global Parenteral Drugs Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Parenteral Drugs Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Parenteral Drugs Sales by Country (2020-2031)
7.3.1 Global Parenteral Drugs Sales by Country (2020-2025)
7.3.2 Global Parenteral Drugs Sales by Country (2026-2031)
7.4 Global Parenteral Drugs Sales Value by Country (2020-2031)
7.4.1 Global Parenteral Drugs Sales Value by Country (2020-2025)
7.4.2 Global Parenteral Drugs Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Parenteral Drugs Sales Value Growth Rate (2020-2031)
7.5.2 USA Parenteral Drugs Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Parenteral Drugs Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Parenteral Drugs Sales Value Growth Rate (2020-2031)
7.6.2 Canada Parenteral Drugs Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Parenteral Drugs Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Parenteral Drugs Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Parenteral Drugs Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Parenteral Drugs Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Parenteral Drugs Sales Value Growth Rate (2020-2031)
7.8.2 Germany Parenteral Drugs Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Parenteral Drugs Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Parenteral Drugs Sales Value Growth Rate (2020-2031)
7.9.2 France Parenteral Drugs Sales Value Share by Type, 2024 VS 2031
7.9.3 France Parenteral Drugs Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Parenteral Drugs Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Parenteral Drugs Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Parenteral Drugs Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Parenteral Drugs Sales Value Growth Rate (2020-2031)
7.11.2 Italy Parenteral Drugs Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Parenteral Drugs Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Parenteral Drugs Sales Value Growth Rate (2020-2031)
7.12.2 Spain Parenteral Drugs Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Parenteral Drugs Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Parenteral Drugs Sales Value Growth Rate (2020-2031)
7.13.2 Russia Parenteral Drugs Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Parenteral Drugs Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Parenteral Drugs Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Parenteral Drugs Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Parenteral Drugs Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Parenteral Drugs Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Parenteral Drugs Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Parenteral Drugs Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Parenteral Drugs Sales Value Growth Rate (2020-2031)
7.16.2 China Parenteral Drugs Sales Value Share by Type, 2024 VS 2031
7.16.3 China Parenteral Drugs Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Parenteral Drugs Sales Value Growth Rate (2020-2031)
7.17.2 Japan Parenteral Drugs Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Parenteral Drugs Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Parenteral Drugs Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Parenteral Drugs Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Parenteral Drugs Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Parenteral Drugs Sales Value Growth Rate (2020-2031)
7.19.2 India Parenteral Drugs Sales Value Share by Type, 2024 VS 2031
7.19.3 India Parenteral Drugs Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Parenteral Drugs Sales Value Growth Rate (2020-2031)
7.20.2 Australia Parenteral Drugs Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Parenteral Drugs Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Parenteral Drugs Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Parenteral Drugs Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Parenteral Drugs Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Parenteral Drugs Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Parenteral Drugs Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Parenteral Drugs Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Parenteral Drugs Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Parenteral Drugs Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Parenteral Drugs Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Parenteral Drugs Sales Value Growth Rate (2020-2031)
7.24.2 Chile Parenteral Drugs Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Parenteral Drugs Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Parenteral Drugs Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Parenteral Drugs Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Parenteral Drugs Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Parenteral Drugs Sales Value Growth Rate (2020-2031)
7.26.2 Peru Parenteral Drugs Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Parenteral Drugs Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Parenteral Drugs Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Parenteral Drugs Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Parenteral Drugs Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Parenteral Drugs Sales Value Growth Rate (2020-2031)
7.28.2 Israel Parenteral Drugs Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Parenteral Drugs Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Parenteral Drugs Sales Value Growth Rate (2020-2031)
7.29.2 UAE Parenteral Drugs Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Parenteral Drugs Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Parenteral Drugs Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Parenteral Drugs Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Parenteral Drugs Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Parenteral Drugs Sales Value Growth Rate (2020-2031)
7.31.2 Iran Parenteral Drugs Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Parenteral Drugs Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Parenteral Drugs Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Parenteral Drugs Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Parenteral Drugs Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Albert David
8.1.1 Albert David Comapny Information
8.1.2 Albert David Business Overview
8.1.3 Albert David Parenteral Drugs Sales, Value and Gross Margin (2020-2025)
8.1.4 Albert David Parenteral Drugs Product Portfolio
8.1.5 Albert David Recent Developments
8.2 Aspen Holdings
8.2.1 Aspen Holdings Comapny Information
8.2.2 Aspen Holdings Business Overview
8.2.3 Aspen Holdings Parenteral Drugs Sales, Value and Gross Margin (2020-2025)
8.2.4 Aspen Holdings Parenteral Drugs Product Portfolio
8.2.5 Aspen Holdings Recent Developments
8.3 AXA Parenterals Ltd
8.3.1 AXA Parenterals Ltd Comapny Information
8.3.2 AXA Parenterals Ltd Business Overview
8.3.3 AXA Parenterals Ltd Parenteral Drugs Sales, Value and Gross Margin (2020-2025)
8.3.4 AXA Parenterals Ltd Parenteral Drugs Product Portfolio
8.3.5 AXA Parenterals Ltd Recent Developments
8.4 BAG Healthcare
8.4.1 BAG Healthcare Comapny Information
8.4.2 BAG Healthcare Business Overview
8.4.3 BAG Healthcare Parenteral Drugs Sales, Value and Gross Margin (2020-2025)
8.4.4 BAG Healthcare Parenteral Drugs Product Portfolio
8.4.5 BAG Healthcare Recent Developments
8.5 Baxter Healthcare Corporation
8.5.1 Baxter Healthcare Corporation Comapny Information
8.5.2 Baxter Healthcare Corporation Business Overview
8.5.3 Baxter Healthcare Corporation Parenteral Drugs Sales, Value and Gross Margin (2020-2025)
8.5.4 Baxter Healthcare Corporation Parenteral Drugs Product Portfolio
8.5.5 Baxter Healthcare Corporation Recent Developments
8.6 Beximco Pharma
8.6.1 Beximco Pharma Comapny Information
8.6.2 Beximco Pharma Business Overview
8.6.3 Beximco Pharma Parenteral Drugs Sales, Value and Gross Margin (2020-2025)
8.6.4 Beximco Pharma Parenteral Drugs Product Portfolio
8.6.5 Beximco Pharma Recent Developments
8.7 BML Parenteral Drugs
8.7.1 BML Parenteral Drugs Comapny Information
8.7.2 BML Parenteral Drugs Business Overview
8.7.3 BML Parenteral Drugs Parenteral Drugs Sales, Value and Gross Margin (2020-2025)
8.7.4 BML Parenteral Drugs Parenteral Drugs Product Portfolio
8.7.5 BML Parenteral Drugs Recent Developments
8.8 Cook Pharmica
8.8.1 Cook Pharmica Comapny Information
8.8.2 Cook Pharmica Business Overview
8.8.3 Cook Pharmica Parenteral Drugs Sales, Value and Gross Margin (2020-2025)
8.8.4 Cook Pharmica Parenteral Drugs Product Portfolio
8.8.5 Cook Pharmica Recent Developments
8.9 Ostuka Pharmaceutical
8.9.1 Ostuka Pharmaceutical Comapny Information
8.9.2 Ostuka Pharmaceutical Business Overview
8.9.3 Ostuka Pharmaceutical Parenteral Drugs Sales, Value and Gross Margin (2020-2025)
8.9.4 Ostuka Pharmaceutical Parenteral Drugs Product Portfolio
8.9.5 Ostuka Pharmaceutical Recent Developments
8.10 Ozon Pharmaceuticals Ltd
8.10.1 Ozon Pharmaceuticals Ltd Comapny Information
8.10.2 Ozon Pharmaceuticals Ltd Business Overview
8.10.3 Ozon Pharmaceuticals Ltd Parenteral Drugs Sales, Value and Gross Margin (2020-2025)
8.10.4 Ozon Pharmaceuticals Ltd Parenteral Drugs Product Portfolio
8.10.5 Ozon Pharmaceuticals Ltd Recent Developments
8.11 Patheon
8.11.1 Patheon Comapny Information
8.11.2 Patheon Business Overview
8.11.3 Patheon Parenteral Drugs Sales, Value and Gross Margin (2020-2025)
8.11.4 Patheon Parenteral Drugs Product Portfolio
8.11.5 Patheon Recent Developments
8.12 PSI Ltd
8.12.1 PSI Ltd Comapny Information
8.12.2 PSI Ltd Business Overview
8.12.3 PSI Ltd Parenteral Drugs Sales, Value and Gross Margin (2020-2025)
8.12.4 PSI Ltd Parenteral Drugs Product Portfolio
8.12.5 PSI Ltd Recent Developments
8.13 Southwest Pharmaceutical
8.13.1 Southwest Pharmaceutical Comapny Information
8.13.2 Southwest Pharmaceutical Business Overview
8.13.3 Southwest Pharmaceutical Parenteral Drugs Sales, Value and Gross Margin (2020-2025)
8.13.4 Southwest Pharmaceutical Parenteral Drugs Product Portfolio
8.13.5 Southwest Pharmaceutical Recent Developments
8.14 B. Braun
8.14.1 B. Braun Comapny Information
8.14.2 B. Braun Business Overview
8.14.3 B. Braun Parenteral Drugs Sales, Value and Gross Margin (2020-2025)
8.14.4 B. Braun Parenteral Drugs Product Portfolio
8.14.5 B. Braun Recent Developments
8.15 Cisen
8.15.1 Cisen Comapny Information
8.15.2 Cisen Business Overview
8.15.3 Cisen Parenteral Drugs Sales, Value and Gross Margin (2020-2025)
8.15.4 Cisen Parenteral Drugs Product Portfolio
8.15.5 Cisen Recent Developments
8.16 Fresenius
8.16.1 Fresenius Comapny Information
8.16.2 Fresenius Business Overview
8.16.3 Fresenius Parenteral Drugs Sales, Value and Gross Margin (2020-2025)
8.16.4 Fresenius Parenteral Drugs Product Portfolio
8.16.5 Fresenius Recent Developments
8.17 Pfizer (Hospira)
8.17.1 Pfizer (Hospira) Comapny Information
8.17.2 Pfizer (Hospira) Business Overview
8.17.3 Pfizer (Hospira) Parenteral Drugs Sales, Value and Gross Margin (2020-2025)
8.17.4 Pfizer (Hospira) Parenteral Drugs Product Portfolio
8.17.5 Pfizer (Hospira) Recent Developments
8.18 Kelun Pharma
8.18.1 Kelun Pharma Comapny Information
8.18.2 Kelun Pharma Business Overview
8.18.3 Kelun Pharma Parenteral Drugs Sales, Value and Gross Margin (2020-2025)
8.18.4 Kelun Pharma Parenteral Drugs Product Portfolio
8.18.5 Kelun Pharma Recent Developments
8.19 Acebright
8.19.1 Acebright Comapny Information
8.19.2 Acebright Business Overview
8.19.3 Acebright Parenteral Drugs Sales, Value and Gross Margin (2020-2025)
8.19.4 Acebright Parenteral Drugs Product Portfolio
8.19.5 Acebright Recent Developments
8.20 SSY Group
8.20.1 SSY Group Comapny Information
8.20.2 SSY Group Business Overview
8.20.3 SSY Group Parenteral Drugs Sales, Value and Gross Margin (2020-2025)
8.20.4 SSY Group Parenteral Drugs Product Portfolio
8.20.5 SSY Group Recent Developments
8.21 Teva Pharmaceutical Industries
8.21.1 Teva Pharmaceutical Industries Comapny Information
8.21.2 Teva Pharmaceutical Industries Business Overview
8.21.3 Teva Pharmaceutical Industries Parenteral Drugs Sales, Value and Gross Margin (2020-2025)
8.21.4 Teva Pharmaceutical Industries Parenteral Drugs Product Portfolio
8.21.5 Teva Pharmaceutical Industries Recent Developments
8.22 Abbott
8.22.1 Abbott Comapny Information
8.22.2 Abbott Business Overview
8.22.3 Abbott Parenteral Drugs Sales, Value and Gross Margin (2020-2025)
8.22.4 Abbott Parenteral Drugs Product Portfolio
8.22.5 Abbott Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Parenteral Drugs Value Chain Analysis
9.1.1 Parenteral Drugs Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Parenteral Drugs Sales Mode & Process
9.2 Parenteral Drugs Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Parenteral Drugs Distributors
9.2.3 Parenteral Drugs Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.